Authors' Reply - Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?

Clinics (Sao Paulo). 2019 Sep 26:74:e1517. doi: 10.6061/clinics/2019/e1517. eCollection 2019.

Authors

Luis Eduardo Miani Gomes¹, Francesca Aparecida Ramos da Silva¹, Lívia Bitencourt Pascoal¹, Renato Lazarin Ricci¹, Guilherme Nogueira², Michel Gardere Camargo¹, Maria de Lourdes Setsuko Ayrizono¹, João José Fagundes¹, Raquel Franco Leal¹

Affiliations

¹ Laboratorio de Investigacao em Doencas Inflamatorias Intestinais, Servico de Coloproctologia, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.
² Laboratorio de Sinalizacao Celular, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Brazil
Crohn Disease*
Humans
Immunosuppressive Agents
Infliximab

Substances

Antibodies, Monoclonal
Immunosuppressive Agents
Infliximab